Product Details
Invega Trinza
Paliperidone Palmitate263 mg/1.315 mL
Prolonged-Release Injectable Suspension
Prefilled Syringe
DIN/PIN/NPN
02455986
Manufacturer
Janssen Inc.
Formulary Listing Date
2018-03-29
Unit Price
1430.6100
Amount MOH Pays
1430.6100
Coverage Status
General Benefit
ODB Formulary Therapeutic Classification
Therapeutic Note
Paliperidone Palmitate 263 mg/1.315 mL Prolonged-Release Injectable Suspension in Prefilled Syringe: For the treatment of schizophrenia or schizoaffective disorders in patients who have: A history of non-adherence AND One of the following: a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents. AND Adequate treatment of using 1-month paliperidone palmitate prolonged-release injectable suspension has been established for at least four months.
ATC Code
N05AX13